Literature DB >> 25482133

Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia.

D Rea1, T Mirault2, E Raffoux1, N Boissel3, A L Andreoli4, P Rousselot5, H Dombret1, E Messas2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25482133     DOI： 10.1038/leu.2014.342

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  13 in total

1.  Severe peripheral arterial disease during nilotinib therapy.

Authors:  Philipp Le Coutre; Delphine Rea; Elisabetta Abruzzese; Hervé Dombret; Malgorzata M Trawinska; Susanne Herndlhofer; Bernd Dörken; Peter Valent
Journal:  J Natl Cancer Inst       Date:  2011-08-02       Impact factor: 13.506

2.  European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts).

Authors:  Joep Perk; Guy De Backer; Helmut Gohlke; Ian Graham; Zeljko Reiner; Monique Verschuren; Christian Albus; Pascale Benlian; Gudrun Boysen; Renata Cifkova; Christi Deaton; Shah Ebrahim; Miles Fisher; Giuseppe Germano; Richard Hobbs; Arno Hoes; Sehnaz Karadeniz; Alessandro Mezzani; Eva Prescott; Lars Ryden; Martin Scherer; Mikko Syvänne; Wilma J M Scholte op Reimer; Christiaan Vrints; David Wood; Jose Luis Zamorano; Faiez Zannad
Journal:  Eur Heart J       Date:  2012-05-03       Impact factor: 29.983

3.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Authors:  Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

4.  Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.

Authors:  Hagop M Kantarjian; Francis J Giles; Kapil N Bhalla; Javier Pinilla-Ibarz; Richard A Larson; Norbert Gattermann; Oliver G Ottmann; Andreas Hochhaus; Jerald P Radich; Giuseppe Saglio; Timothy P Hughes; Giovanni Martinelli; Dong-Wook Kim; Yaping Shou; Neil J Gallagher; Rick Blakesley; Michele Baccarani; Jorge Cortes; Philipp D le Coutre
Journal:  Blood       Date:  2010-11-22       Impact factor: 22.113

5.  Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

Authors:  Ellen Weisberg; Paul W Manley; Werner Breitenstein; Josef Brüggen; Sandra W Cowan-Jacob; Arghya Ray; Brian Huntly; Doriano Fabbro; Gabriele Fendrich; Elizabeth Hall-Meyers; Andrew L Kung; Jürgen Mestan; George Q Daley; Linda Callahan; Laurie Catley; Cara Cavazza; Mohammad Azam; Azam Mohammed; Donna Neuberg; Renee D Wright; D Gary Gilliland; James D Griffin
Journal:  Cancer Cell       Date:  2005-02       Impact factor: 31.743

6.  Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.

Authors:  Karl J Aichberger; Susanne Herndlhofer; Gerit-Holger Schernthaner; Martin Schillinger; Gerlinde Mitterbauer-Hohendanner; Christian Sillaber; Peter Valent
Journal:  Am J Hematol       Date:  2011-04-27       Impact factor: 10.047

Review 7.  Which TKI? An embarrassment of riches for chronic myeloid leukemia patients.

Authors:  Timothy Hughes; Deborah White
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

8.  Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia.

Authors:  Zdenek Racil; Filip Razga; Jana Drapalova; Lucie Buresova; Daniela Zackova; Martina Palackova; Lukas Semerad; Ludmila Malaskova; Martin Haluzik; Jiri Mayer
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

9.  Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib.

Authors:  T D Kim; D Rea; M Schwarz; P Grille; F E Nicolini; G Rosti; L Levato; F J Giles; H Dombret; T Mirault; H Labussière; R Lindhorst; W Haverkamp; I Buschmann; B Dörken; P D le Coutre
Journal:  Leukemia       Date:  2013-03-05       Impact factor: 11.528

Review 10.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Authors:  Michele Baccarani; Michael W Deininger; Gianantonio Rosti; Andreas Hochhaus; Simona Soverini; Jane F Apperley; Francisco Cervantes; Richard E Clark; Jorge E Cortes; François Guilhot; Henrik Hjorth-Hansen; Timothy P Hughes; Hagop M Kantarjian; Dong-Wook Kim; Richard A Larson; Jeffrey H Lipton; François-Xavier Mahon; Giovanni Martinelli; Jiri Mayer; Martin C Müller; Dietger Niederwieser; Fabrizio Pane; Jerald P Radich; Philippe Rousselot; Giuseppe Saglio; Susanne Saußele; Charles Schiffer; Richard Silver; Bengt Simonsson; Juan-Luis Steegmann; John M Goldman; Rüdiger Hehlmann
Journal:  Blood       Date:  2013-06-26       Impact factor: 22.113
View more
  10 in total

Review 1.  Lifelong TKI therapy: how to manage cardiovascular and other risks.

Authors:  Michael J Mauro
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 2.  Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia.

Authors:  Yoshihiro Umezawa; Koji Sasaki
Journal:  Int J Hematol       Date:  2022-09-10       Impact factor: 2.319

3.  Association between a cardiovascular disease risk assessment and the molecular response to tyrosine kinase inhibitors in chronic-phase chronic myeloid leukemia patients.

Authors:  Yuki Osada; Hideki Arakaki; Satoshi Takanashi; Chisako Ito; Yoshinobu Aisa; Tomonori Nakazato
Journal:  Med Oncol       Date:  2017-03-22       Impact factor: 3.064

Review 4.  Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?

Authors:  Gianantonio Rosti; Fausto Castagnetti; Gabriele Gugliotta; Michele Baccarani
Journal:  Nat Rev Clin Oncol       Date:  2016-10-18       Impact factor: 66.675

Review 5.  European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

Authors:  J L Steegmann; M Baccarani; M Breccia; L F Casado; V García-Gutiérrez; A Hochhaus; D-W Kim; T D Kim; H J Khoury; P Le Coutre; J Mayer; D Milojkovic; K Porkka; D Rea; G Rosti; S Saussele; R Hehlmann; R E Clark
Journal:  Leukemia       Date:  2016-04-28       Impact factor: 11.528

6.  Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.

Authors:  Francis J Giles; Delphine Rea; Gianantonio Rosti; Nicholas C P Cross; Juan Luis Steegmann; Laimonas Griskevicius; Philipp le Coutre; Daniel Coriu; Ljubomir Petrov; Gert J Ossenkoppele; Francois-Xavier Mahon; Susanne Saussele; Andrzej Hellmann; Perttu Koskenvesa; Tim H Brümmendorf; Gunther Gastl; Fausto Castagnetti; Beatrice Vincenzi; Jens Haenig; Andreas Hochhaus
Journal:  J Cancer Res Clin Oncol       Date:  2017-03-31       Impact factor: 4.553

Review 7.  Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance.

Authors:  Nazanin Aghel; Diego Hernan Delgado; Jeffrey Howard Lipton
Journal:  Vasc Health Risk Manag       Date:  2017-08-04

Review 8.  Towards a Personalized Treatment of Patients with Chronic Myeloid Leukemia.

Authors:  Florence Rabian; Etienne Lengline; Delphine Rea
Journal:  Curr Hematol Malig Rep       Date:  2019-12       Impact factor: 3.952

Review 9.  Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology.

Authors:  Tienush Rassaf; Matthias Totzeck; Johannes Backs; Carsten Bokemeyer; Michael Hallek; Denise Hilfiker-Kleiner; Andreas Hochhaus; Diana Lüftner; Oliver J Müller; Ulrich Neudorf; Roman Pfister; Stephan von Haehling; Lorenz H Lehmann; Johann Bauersachs
Journal:  Clin Res Cardiol       Date:  2020-05-13       Impact factor: 5.460

Review 10.  Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia.

Authors:  Oren Pasvolsky; Avi Leader; Zaza Iakobishvili; Yishay Wasserstrum; Ran Kornowski; Pia Raanani
Journal:  Cardiooncology       Date:  2015-12-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.